Bradley Saenger CPA, CPA Net Worth

The estimated Net Worth of Bradley Saenger is at least $587 millier dollars as of 14 June 2018. Mr Saenger owns over 300 units of Tonix Pharmaceuticals Corp stock worth over $462 and over the last 8 years he sold TNXP stock worth over $0. In addition, he makes $586,163 as CFO & Treasurer at Tonix Pharmaceuticals Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr CPA TNXP stock SEC Form 4 insiders trading

Mr has made over 3 trades of the Tonix Pharmaceuticals Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 300 units of TNXP stock worth $1,230 on 14 June 2018.

The largest trade he's ever made was buying 2,000 units of Tonix Pharmaceuticals Corp stock on 21 June 2016 worth over $4,000. On average, Mr trades about 307 units every 52 days since 2016. As of 14 June 2018 he still owns at least 3,079 units of Tonix Pharmaceuticals Corp stock.

You can see the complete history of Mr Saenger stock trades at the bottom of the page.

Mr. Bradley Saenger CPA, CPA biography

Bradley Saenger CPA, CPA is the CFO & Treasurer at Tonix Pharmaceuticals Corp.

What is the salary of Mr CPA?

As the CFO & Treasurer of Tonix Pharmaceuticals Corp, the total compensation of Mr CPA at Tonix Pharmaceuticals Corp is $586,163. There are 5 executives at Tonix Pharmaceuticals Corp getting paid more, with Seth Lederman having the highest compensation of $1,288,270.

How old is Mr CPA?

Mr CPA is 47, he's been the CFO & Treasurer of Tonix Pharmaceuticals Corp since . There are 13 older and 2 younger executives at Tonix Pharmaceuticals Corp. The oldest executive at Tonix Pharmaceuticals Holding Corp is Adeoye Olukotun, 75, who is the Independent Director.

What's Mr CPA's mailing address?

Bradley's mailing address filed with the SEC is C/O TONIX PHARMACEUTICALS HOLDING CORP, 26 MAIN ST., SUITE 101, CHATHAM, NJ, 07928.

Insiders trading at Tonix Pharmaceuticals Corp

Over the last 12 years, insiders at Tonix Pharmaceuticals Corp have traded over $155,884 worth of Tonix Pharmaceuticals Corp stock and bought 1,820,071 units worth $3,399,062 . The most active insiders traders include Ernest Mario, Seth Lederman et Bruce Daugherty. On average, Tonix Pharmaceuticals Corp executives and independent directors trade stock every 32 days with the average trade being worth of $2,734. The most recent stock trade was executed by Seth Lederman on 29 June 2022, trading 20,000 units of TNXP stock currently worth $34,200.

What does Tonix Pharmaceuticals Corp do?

tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.

Complete history of Mr Saenger stock trades at Tonix Pharmaceuticals Corp

Tonix Pharmaceuticals Corp executives and stock owners

Tonix Pharmaceuticals Corp executives and other stock owners filed with the SEC include:

• Seth Lederman,
  Chairman of the Board, President, Chief Executive Officer
• Dr. Seth Lederman M.D.,
  Co-Founder, Pres, CEO & Chairman
• Dr. Seth Lederman,
  Co-Founder, Pres, CEO & Chairman
• Dr. Gregory M. Sullivan M.D.,
  Chief Medical Officer & Sec.
• Gregory Sullivan,
  Secretary, Chief Medical Officer
• Bradley Saenger CPA, CPA,
  CFO & Treasurer
• Bradley Saenger,
  Chief Financial Officer, Treasurer
• Richard Bagger,
  Director
• Herbert Harris,
  Executive Vice President - Translational Medicine
• David Grange,
  Independent Director
• Margaret Bell,
  Independent Director
• James Treco,
  Lead Independent Director
• Adeoye Olukotun,
  Independent Director
• Daniel Goodman,
  Independent Director
• Jessica Morris,
  Chief Operating Officer
• Dr. Sina Bavari Ph.D.,
  Exec. VP of Infectious Disease R&D
• Dr. Anthony Macaluso Ph.D.,
  Exec. VP of Strategic Devel.
• Dr. Darryl Rideout Ph.D.,
  Exec. VP of Experimental Chemistry
• Siobhan Fogarty B.Sc., M.Sc.,
  Exec. VP of Product Devel.
• Dr. Bruce L. Daugherty M.B.A., Ph.D.,
  Exec. VP of Research
• Dr. Herbert W. Harris M.D., Ph.D.,
  Exec. VP of Translational Medicine
• Dr. R. Michael Gendreau,
  Consultant
• Dr. Daniel J. Clauw M.D.,
  Consultant
• Dr. Ronald R. Notvest,
  Exec. VP of Commercial Planning and Devel.
• Jessica Edgar Morris,
  Chief Operating Officer
• Charles E Iv Mather,
  Director
• Ernest Mario,
  Director
• John B Rhodes,
  Director
• Samuel R Saks,
  Director
• Patrick P Grace,
  Director
• Bruce Daugherty,
  See Remarks
• Stuart Davidson,
  Director
• Donald J Kellerman,
  See Remarks
• Leland Gershell,
  CFO and Treasurer
• Carolyn E. Taylor,
  Director
• Richard Newcomb Stillwell,
  Director